FRANKFURT, March 9 (Reuters) - Roche's shares dropped more than 5% on Monday as the Swiss drugmaker failed to show that its ...

A Roche Holding AG study of its experimental breast-cancer drug in combination with another treatment failed to meet the ...

March 9 (Reuters) - Bristol Myers Squibb on Monday said its experimental cancer drug met the main goal of a late-stage study.

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

The FDA's cancer advisors will discuss AstraZeneca’s application for the oral SERD camizestrant in breast cancer and the AKT ...

A phase 3 trial of Roche’s giredestrant in first-line breast cancer patients has missed its primary endpoint, tarnishing the record of a drug that hit the mark in adjuvant and second-line settings.

Wall Street's verdict on Prasad, generic semaglutide's new pricing, and other biotech news ...

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of ...

Roche’s shares tumbled nearly 5% on news that a key pillar in the five-pronged clinical plan for the breast cancer asset ...

Many therapeutic molecules used in cancer treatments are highly toxic, often harming healthy tissues and causing significant ...